Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abbott Laboratories
(NY:
ABT
)
117.26
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abbott Laboratories
< Previous
1
2
3
4
5
6
Next >
MarketBeat Week in Review – 10/14 - 10/18
October 19, 2024
Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
October 16, 2024
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results align with the trend.
Via
MarketBeat
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
September 17, 2024
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
September 09, 2024
Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases
Via
MarketBeat
Abbott Laboratories (NYSE: ABT) Records 52-Week High Friday Morning
February 23, 2024
Via
Investor Brand Network
Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally
August 23, 2024
Medtronic's Q1 FY2025 results were driven by its diabetes products, and new offerings in development or pending FDA approval could fuel future performance.
Via
MarketBeat
Exposures
Product Safety
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
August 09, 2024
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
July 22, 2024
Intuitive Surgical is an AI stock that you can buy and hold forever. Its business is health care; it makes profits, and health care is growing
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why This Leading Health Stock is a Buy No Matter the Market Move
July 18, 2024
Abbott's reliable dividend is more reliable than ever and is expected to continue growing at a high-single to low-double-digit CAGR.
Via
MarketBeat
Exposures
COVID-19
U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist
July 11, 2024
From
Financial Buzz Media
Via
GlobeNewswire
AbbVie Stock: A Perfect Dip for Investors to Buy
July 03, 2024
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors
Via
MarketBeat
Topics
ETFs
Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important
May 21, 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:ABT),(NASDAQ:CELH),(NASDAQ:MNST),(NYSE:BRBR) EQNX::TICKER_END
Via
FinancialNewsMedia
Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important
May 21, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
April 30, 2024
Via
AB Newswire
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
April 30, 2024
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook.
Via
MarketBeat
Abbott Laboratories Outlook is Healthy: Buy the Dip
April 17, 2024
Abbott Laboratories had a steady quarter, producing growth, better-than-expected earnings, and raising the guidance. Analysts see the stock moving higher.
Via
MarketBeat
Exposures
COVID-19
Johnson & Johnson is as Cheap as it’s Going to Get
April 16, 2024
Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely.
Via
MarketBeat
DexCom Stock Gains from GLP-1 Diabetic Users
April 02, 2024
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
Via
MarketBeat
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
March 20, 2024
Via
AB Newswire
Topics
Death
Exposures
Death
Medtronic is a Dividend Aristocrat That Keeps Gaining
March 11, 2024
A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector
Via
MarketBeat
Are These 5 Undervalued Stocks Ready to Break Out?
March 08, 2024
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.
Via
MarketBeat
4 med tech stocks with improving prognosis for 2024
January 31, 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025.
Via
MarketBeat
Exposures
COVID-19
Abbott Laboratories on track for new highs in 2024
January 25, 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact.
Via
MarketBeat
Exposures
COVID-19
Johnson & Johnson's stock price is at a critical turning point
January 23, 2024
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Medtronic receives FDA approval for deep brain stimulation system
January 17, 2024
Medical device maker Medtronic PLC (NYSE: MDT) received U.S. FDA approval for its implantable medical device called the Percept PC Deep Brain Stimulation (DBS)
Via
MarketBeat
Exposures
Product Safety
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
January 08, 2024
From
Tandem Diabetes Care, Inc.
Via
Business Wire
AbbVie continues shopping spree with biotech buyout
December 12, 2023
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend.
Via
MarketBeat
Medtronic: oversold, overextended high yield reversal in play
November 22, 2023
The reversal in Medtronic has been brewing for some time but is gaining traction after strong second quarter earnings that came with improved guidance
Via
MarketBeat
Exposures
COVID-19
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
November 17, 2023
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Are These 3 Dividend Aristocrats Undervalued Hidden Gems?
October 25, 2023
Dividend aristocrats Caterpillar, NextEra, and Clorox have shown resilience in challenging times. These may offer opportunities as they are trading off highs.
Via
MarketBeat
Exposures
COVID-19
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.